Natixis’s Merck MRK Stock Holding History

Natixis’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-800	Closed	-$69K	–	1262
2022 Q3	$69K	Sell	800 -279	-26%	-$24.9K	﹤0.01%	999
2022 Q2	$99K	Buy	+1,079	New	+$95.7K	﹤0.01%	1053

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Natixis's MRK Position: Q2 2026 in Review

Natixis reduced its Merck (MRK) stake by 45% in Q2 2026, selling an estimated $26.9M and leaving 280,187 shares worth $36M. The position accounts for 0.14% of the portfolio, ranked #103.

Natixis first reported a position in MRK in Q2 2013 and has held it in 49 quarters since. The position peaked at $275M in Q3 2022. 3,841 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Natixis held 280,187 shares of Merck worth $36M as of Q2 2026.
Natixis sold 229,869 Merck shares in Q2 2026, an estimated $26.9M.
Merck made up 0.14% of Natixis's portfolio in Q2 2026, its #103 holding.
Natixis first reported a position in Merck in Q2 2013 and has held it in 49 quarters since.
Natixis's Merck position peaked at $275M in Q3 2022.
3,841 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.